H.C. Wainwright analyst Raghuram Selvaraju reiterated a Neutral rating and $2.50 price target on Inovio Pharmaceuticals (NASDAQ: INO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments